Andrew Callos, Executive Vice President and Chief Commercial Officer of Cytokinetics Inc (NASDAQ:CYTK), filed a Form 4 on August 31, 2026, disclosing the exercise of 10,000 stock options and the same-day sale of 10,000 shares of common stock.

Key Highlights

  • Option exercise: Andrew Callos exercised 10,000 non-qualified stock options at an exercise price of $23.26 per share on August 31, 2026.
  • Shares sold: 10,000 shares of common stock were disposed of at $70.24 per share on August 31, 2026.
  • Remaining ownership: Following the transactions, Callos directly beneficially owned 58,555 shares of common stock.
  • Options fully exercised: After the exercise, the reported non-qualified stock option position stands at 0 derivative securities remaining.
  • Rule 10b5-1 plan: The filing indicates the transaction was made pursuant to a contract, instruction, or written plan intended to satisfy the affirmative defense conditions of Rule 10b5-1(c).

Details of the Callos Option Exercise and Share Sale at Cytokinetics

According to the filing, Andrew Callos, serving as EVP and Chief Commercial Officer of Cytokinetics Inc, executed two transactions on August 31, 2026. First, he exercised 10,000 non-qualified stock options with a conversion price of $23.26, acquiring 10,000 shares of common stock. The options had a date exercisable of March 31, 2022, and an expiration date of March 31, 2031, with a reported price of $0 for the derivative security itself. Prior to this exercise, the filing shows Callos held 68,555 shares directly before the sale transaction was recorded.

In the same session, the filing discloses that Callos disposed of 10,000 shares of common stock at a price of $70.24 per share, coded as an open-market sale. Following both transactions, his direct beneficial ownership in Cytokinetics common stock stood at 58,555 shares, according to the filing. The form notes the transaction was executed pursuant to a Rule 10b5-1(c) written plan.

The filing explains that the original stock options were granted with a vesting schedule in which one-quarter of the underlying shares vested on the one-year anniversary of the grant date, with the remainder vesting monthly at a rate of 1/48th of the total shares over the following 36 months, subject to continued employment. The Form 4 was signed by John O. Faurescu as attorney-in-fact for Mr. Callos on August 31, 2026.

What Was Disclosed

Cytokinetics EVP Andrew Callos reported exercising 10,000 stock options at $23.26 and selling 10,000 shares at $70.24 on August 31, 2026, under a Rule 10b5-1 plan, leaving him with 58,555 directly held shares.